Peptide biosensors for anticancer drugs: Design in silico to work in denaturizing environment

Filomena Guida, Anna Battisti, Ivan Gladich, Mauro Buzzo, Elena Marangon, Luciana Giodini, Giuseppe Toffoli, Alessandro Laio, Federico Berti

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

One of the main targets in current clinical oncology is the development of a cheap device capable of monitoring in real-time the concentration of a drug in the blood of a patient. This would allow fine-tuning the dosage according to the patient's metabolism, a key condition to reduce side effects. By using surface plasmon resonance and fluorescence spectroscopy we here show that short peptides designed in silico by a recently developed algorithm are capable of binding the anticancer drug irinotecan (CPT-11) with micromolar affinity. Importantly, the recognition takes place in the denaturating solution used in standard therapeutic drug monitoring to detach the drug from the proteins that are present in human plasma, and some of the peptides are capable of distinguishing CPT-11 from its metabolite SN-38. These results suggest that the in silico design of small artificial peptides is now a viable route for designing sensing units, opening a wide range of applications in diagnostic and clinical areas.

Original languageEnglish
Pages (from-to)298-303
Number of pages6
JournalBiosensors and Bioelectronics
Volume100
DOIs
Publication statusPublished - 15 Feb 2018

Fingerprint

irinotecan
Drug Design
Biosensing Techniques
Biosensors
Computer Simulation
Peptides
Pharmaceutical Preparations
Plasma (human)
Oncology
Monitoring
Fluorescence spectroscopy
Surface plasmon resonance
Metabolites
Metabolism
Medical Oncology
Surface Plasmon Resonance
Drug Monitoring
Fluorescence Spectrometry
Blood
Tuning

Keywords

  • Drug monitoring
  • In silico design
  • Irinotecan
  • Peptides

ASJC Scopus subject areas

  • Biotechnology
  • Biophysics
  • Biomedical Engineering
  • Electrochemistry

Cite this

Peptide biosensors for anticancer drugs : Design in silico to work in denaturizing environment. / Guida, Filomena; Battisti, Anna; Gladich, Ivan; Buzzo, Mauro; Marangon, Elena; Giodini, Luciana; Toffoli, Giuseppe; Laio, Alessandro; Berti, Federico.

In: Biosensors and Bioelectronics, Vol. 100, 15.02.2018, p. 298-303.

Research output: Contribution to journalArticle

Guida, F, Battisti, A, Gladich, I, Buzzo, M, Marangon, E, Giodini, L, Toffoli, G, Laio, A & Berti, F 2018, 'Peptide biosensors for anticancer drugs: Design in silico to work in denaturizing environment', Biosensors and Bioelectronics, vol. 100, pp. 298-303. https://doi.org/10.1016/j.bios.2017.09.012
Guida, Filomena ; Battisti, Anna ; Gladich, Ivan ; Buzzo, Mauro ; Marangon, Elena ; Giodini, Luciana ; Toffoli, Giuseppe ; Laio, Alessandro ; Berti, Federico. / Peptide biosensors for anticancer drugs : Design in silico to work in denaturizing environment. In: Biosensors and Bioelectronics. 2018 ; Vol. 100. pp. 298-303.
@article{3efe69dfcefa41a59c8c3b2bf07d74e1,
title = "Peptide biosensors for anticancer drugs: Design in silico to work in denaturizing environment",
abstract = "One of the main targets in current clinical oncology is the development of a cheap device capable of monitoring in real-time the concentration of a drug in the blood of a patient. This would allow fine-tuning the dosage according to the patient's metabolism, a key condition to reduce side effects. By using surface plasmon resonance and fluorescence spectroscopy we here show that short peptides designed in silico by a recently developed algorithm are capable of binding the anticancer drug irinotecan (CPT-11) with micromolar affinity. Importantly, the recognition takes place in the denaturating solution used in standard therapeutic drug monitoring to detach the drug from the proteins that are present in human plasma, and some of the peptides are capable of distinguishing CPT-11 from its metabolite SN-38. These results suggest that the in silico design of small artificial peptides is now a viable route for designing sensing units, opening a wide range of applications in diagnostic and clinical areas.",
keywords = "Drug monitoring, In silico design, Irinotecan, Peptides",
author = "Filomena Guida and Anna Battisti and Ivan Gladich and Mauro Buzzo and Elena Marangon and Luciana Giodini and Giuseppe Toffoli and Alessandro Laio and Federico Berti",
year = "2018",
month = "2",
day = "15",
doi = "10.1016/j.bios.2017.09.012",
language = "English",
volume = "100",
pages = "298--303",
journal = "Biosensors and Bioelectronics",
issn = "0956-5663",
publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Peptide biosensors for anticancer drugs

T2 - Design in silico to work in denaturizing environment

AU - Guida, Filomena

AU - Battisti, Anna

AU - Gladich, Ivan

AU - Buzzo, Mauro

AU - Marangon, Elena

AU - Giodini, Luciana

AU - Toffoli, Giuseppe

AU - Laio, Alessandro

AU - Berti, Federico

PY - 2018/2/15

Y1 - 2018/2/15

N2 - One of the main targets in current clinical oncology is the development of a cheap device capable of monitoring in real-time the concentration of a drug in the blood of a patient. This would allow fine-tuning the dosage according to the patient's metabolism, a key condition to reduce side effects. By using surface plasmon resonance and fluorescence spectroscopy we here show that short peptides designed in silico by a recently developed algorithm are capable of binding the anticancer drug irinotecan (CPT-11) with micromolar affinity. Importantly, the recognition takes place in the denaturating solution used in standard therapeutic drug monitoring to detach the drug from the proteins that are present in human plasma, and some of the peptides are capable of distinguishing CPT-11 from its metabolite SN-38. These results suggest that the in silico design of small artificial peptides is now a viable route for designing sensing units, opening a wide range of applications in diagnostic and clinical areas.

AB - One of the main targets in current clinical oncology is the development of a cheap device capable of monitoring in real-time the concentration of a drug in the blood of a patient. This would allow fine-tuning the dosage according to the patient's metabolism, a key condition to reduce side effects. By using surface plasmon resonance and fluorescence spectroscopy we here show that short peptides designed in silico by a recently developed algorithm are capable of binding the anticancer drug irinotecan (CPT-11) with micromolar affinity. Importantly, the recognition takes place in the denaturating solution used in standard therapeutic drug monitoring to detach the drug from the proteins that are present in human plasma, and some of the peptides are capable of distinguishing CPT-11 from its metabolite SN-38. These results suggest that the in silico design of small artificial peptides is now a viable route for designing sensing units, opening a wide range of applications in diagnostic and clinical areas.

KW - Drug monitoring

KW - In silico design

KW - Irinotecan

KW - Peptides

UR - http://www.scopus.com/inward/record.url?scp=85029598053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029598053&partnerID=8YFLogxK

U2 - 10.1016/j.bios.2017.09.012

DO - 10.1016/j.bios.2017.09.012

M3 - Article

C2 - 28942212

AN - SCOPUS:85029598053

VL - 100

SP - 298

EP - 303

JO - Biosensors and Bioelectronics

JF - Biosensors and Bioelectronics

SN - 0956-5663

ER -